These results suggest that HER2-mediated bypassing signal causes resistance to EGFR inhibitors; therefore, HER2 blockade agents could potentially exert anticancer efficacy or recover the susceptibility to EGFR inhibitors in patients with HER2-amplified cancers. The gene discussed is EGFR; the disease is cancer.